Hims Hers Really Growth Stock Faces Reality Check Now
Hims & Hers Health shifts to selling branded Wegovy and Ozempic after a settlement with Novo Nordisk, reversing regul...
A practical comparison of retirement index funds and target date funds, outlining when each may be the smarter pick for different retirement goals.
26,044 articlesHims & Hers Health shifts to selling branded Wegovy and Ozempic after a settlement with Novo Nordisk, reversing regul...
Solana turns six as it pivots from meme culture to on-chain equity markets. The network now hosts 200+ tokenized stoc...
A high-profile crypto photo shoot has reignited debates about credibility, PR tactics, and the road ahead for a marke...
A former hedge-fund executive warns that investors dangerously complacent about Iran conflict risks as oil volatility...
A SpaceX IPO could reshape growth investing, creating upside for Rivian and other high-growth names. This guide break...
AI-driven threats are accelerating demand for security software, and a trio of under-$30 cyber names could offer mean...
A high-earning saver turned a sharp income-to-spending gap into cash flow by investing in rental properties, deliveri...
Microsoft accelerates its AI push to reclaim leadership as market re-pricing tests margins. Nadella reshapes teams an...
Four major tech players are pouring hundreds of billions into AI infrastructure in 2026 while trimming payrolls. Mean...
Shrey Parikh outpaced rivals in a tense lightning-round finale, spelling 32 words correctly in 90 seconds to become t...
Hewlett Packard Enterprise beats expectations, pulling forward its 2028 targets by two years as AI infrastructure dem...
Blockchain investigator ZachXBT raises red flags about Rain Protocol, citing on-chain patterns and a lofty market cap...